hIL1RL1/hIL4/hIL4R

Fig1. Expression of hIL1RL1 on CD4+ T cells in spleen in hIL1RL1/hIL4/hIL4R tKI mice.

Fig2. Expression of hIL1RL1 on mast cells in bone marrow in hIL1RL1/hIL4/hIL4R tKI mice.

Fig3. Detection of soluble form hIL4RA (A) and mIL4RA (B) expression in hIL4RA mice by ELISA. 

Abbr. HO: homozygote; WT: Wild type; ND: Not detected.

Fig4. Analysis of hIL4R expression in the spleen in hIL4/hIL4R dKI mice by FACS. 

Fig5. Evaluation of an Anti-huIL4Ra mAb in the OXA-Induced Atopic Dermatitis Model in hIL4/hIL4Ra dKI Mice. 

Both dupilumab and Dexamethasone ameliorate overall atopic dermatitis activity in OXA - challenged ears, but only Dexamethasone worked in back skin. (In cooperation with CrownBio)

Fig6. Dupilumab significantly mitigates inflammatory cell infiltration in lesioned ear. (In cooperation with CrownBio) 

Note: Inflammatory cell infiltration is indicated by black arrows, 10X images

Fig7. Low dose dupilumab significantly mitigates inflammatory cell infiltration in lesioned skin.  (In cooperation with CrownBio) 

Note: Inflammatory cell infiltration is indicated by black arrows, 10X images

Fig8. Dexamethasone and dupilumab treatments are well tolerated. Both significantly reduced IgE levels in serum but not spleen weight. (In cooperation with CrownBio) 

Ordinary one-way ANOVA were applied for analysis compared to Isotype group, *p<0.05, **p<0.01, *** p<0.001.

Fig9. Repeated OXA-induced Th2 cytokine production (hIL-4 elevation) and dupilumab treatment significantly reduces IL-6 and KC/GRO levels in lesioned ear. (In cooperation with CrownBio) 

Ordinary one-way ANOVA were applied for analysis compared to Isotype group, *p<0.05, **p<0.01, *** p<0.001.

Fig10. Repeated OXA-induced Th2 cytokine production (hIL-4 elevation) and dupilumab treatment significantly reduces IL-5 and IL-2 levels in lesioned skin. (In cooperation with CrownBio) 

Ordinary one-way ANOVA were applied for analysis compared to Isotype group, *p<0.05, **p<0.01, *** p<0.001.